Joinn profits slide as lab monkey build-up backfires
The leading provider of pre-clinical drug research has predicted its first-half profits will plummet between 70% and 80% due to the falling value of its lab animals Key Takeaways: Joinn…
Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
The leading Chinese CXO posted record revenue and strong profits last year, but its growth started to slow in the fourth quarter Key Takeaways: Wuxi AppTec’s chemical business doubled last…
What Pandemic? Joinn Lab Posts Bumper Profit Despite Covid Disruptions
Less affected by Covid-control measures that have clobbered many Chinese businesses, the pre-clinical contract research organization’s profit more than doubled in the first three quarters of 2022 Key Takeaways: Joinn…
